The research of lenvatinib on KIF5B RET positive adenocarcinoma of the lung has entered phase II (nct01877083), and its clinical experiments combined with pembrolizumab on non-small cell lung cancer has entered phase III (nct03829332, nct04676412, nct03976375). This evidence concerns the gene KIF5B and lung adenocarcinoma.